Use of substituted pyranone acid derivatives for the treatment of metabolic syndromeThe invention relates to the use of substituted pyranone acid derivatives and their physiologically acceptable salts for producing medicaments for the treatment of metabolic syndrome. The invention also relates to the use of compounds of formula (I), in which the radicals are defined as cited in the description, and their physiologically acceptable salts for producing a medicament for the treatment of metabolic syndrome.Formula i chemical compound and physiologically acceptable salt thereof are used for the treatment of purposes in the medicine of metabolism syndrome in preparation:whereinr1 is h, f, cl, br, i, oh, cf 3, no 2, cn, ocf 3, nh 2, nh (c 1-c 6)-alkyl, n ((c 1-c 6)-alkyl) 2, sf 5, so 2-ch 3, cooh, coo-(c 1-c 6)-alkyl, conh 2, (c 1-c 20)-alkyl, (c 3-c 20)-cycloalkyl, (c 2-c 20)-alkenyl, (c 2-c 20)-alkynyl, aryl, heterocyclic radical are wherein at described (c 1-c 20)-alkyl and (c 2-c 20in the)-alkenyl, one or more each-ch 2-or-the ch-group can be substituted by-o-and wherein said alkyl, cycloalkyl, alkenyl, alkynyl, aryl and heterocyclic radical can be by following single replace or polysubstituted: f, cl, br, i, cf 3, no 2, n 3, cn ,=o, cooh, coo (c 1-c 6)-alkyl, conh 2, conh (c 1-c 6)-alkyl, con[(c 1-c 6)-alkyl] 2, cycloalkyl, (c 1-c 10)-alkyl, (c 2-c 6)-alkenyl, (c 2-c 6)-alkynyl, o-(c 1-c 6)-alkyl, o-co-(c 1-c 6)-alkyl, o-co-(c 1-c 6)-aryl, o-co-(c 1-c 6)-heterocyclic radical; be h, f, cl, br, i, oh, cf 3, no 2, cn, ocf 3, nh 2, nh (c 1-c 6)-alkyl, n ((c 1-c 6)-alkyl) 2, sf 5, so 2-ch 3, cooh, coo-(c 1-c 6)-alkyl, conh 2, (c 1-c 20)-alkyl, (c 3-c 20)-cycloalkyl, (c 2-c 20)-alkenyl, (c 2-c 20)-alkynyl, aryl, heterocyclic radical are wherein at described (c 1-c 20)-alkyl and (c 2-c 20in the)-alkenyl, one or more each-ch 2-or-the ch-group can be substituted by-o-and wherein said alkyl, cycloalkyl, alkenyl, alkynyl, aryl and heterocyclic radical can be by following single replace or polysubstituted: f, cl, br, i, cf 3, no 2, n 3, cn ,=o, cooh, coo (c 1-c 6)-alkyl, conh 2, conh (c 1-c 6)-alkyl, con[(c 1-c 6)-alkyl] 2, cycloalkyl, (c 1-c 10)-alkyl, (c 2-c 6)-alkenyl, (c 2-c 6)-alkynyl, o-(c 1-c 6)-alkyl, o-co-(c 1-c 6)-alkyl, o-co-(c 1-c 6)-aryl, o-co-(c 1-c 6)-heterocyclic radical; po 3h 2, p (o) (o alkyl) 2, (c 1-c 6)-alkylidene-p (o) (o alkyl) 2, o-p (o) (oh) 2, o-p (o) (o alkyl) 2, so 3h, so 2-nh 2, so 2nh (c 1-c 6)-alkyl, so 2n[(c 1-c 6)-alkyl] 2, s-(c 1-c 6)-alkyl, s-(ch 2) n-aryl, s-(ch 2) n-heterocyclic radical, so-(c 1-c 6)-alkyl, so-(ch 2) n-aryl, so-(ch 2) n-heterocyclic radical, so 2-(c 1-c 6)-alkyl, so 2-(ch 2) n-aryl, so 2-(ch 2) n-heterocyclic radical, so 2-nh (ch 2) n-aryl, so 2-nh (ch 2) n-heterocyclic radical, so 2-n ((c 1-c 6)-alkyl) (ch 2) n-aryl, so 2-n ((c 1-c 6)-alkyl) (ch 2) n-heterocyclic radical, so 2-n ((ch 2) n-aryl) 2, so 2-n ((ch 2) n-heterocyclic radical) 2, wherein n=0-6 and described aryl or heterocyclic radical can be by f, cl, br, oh, cf 3, sf 5, no 2, cn, ocf 3, o-(c 1-c 6)-alkyl, (c 1-c 6)-alkyl, nh 2replace twice at the most; c (nh) (nh 2), nh 2, nh-(c 1-c 6)-alkyl, n ((c 1-c 6)-alkyl) 2, nh (c 1-c 7)-acyl group, nh-co-(c 1-c 6)-alkyl, nh-coo-(c 1-c 6)-alkyl, nh-co-aryl, nh-co-heterocyclic radical, nh-coo-aryl, nh-coo-heterocyclic radical, nh-co-nh-(c 1-c 6)-alkyl), nh-co-nh-aryl, nh-co-nh-heterocyclic radical, n[(c 1-c 6)-alkyl]-co-(c 1-c 6)-alkyl, n[(c 1-c 6)-alkyl]-coo-(c 1-c 6)-alkyl, n[(c 1-c 6)-alkyl]-co-aryl, n[(c 1-c 6)-alkyl]-co-heterocyclic radical, n[(c 1-c 6)-alkyl]-coo-aryl, n[(c 1-c 6)-alkyl]-coo-heterocyclic radical, n[(c 1-c 6)-alkyl]-co-nh-(c 1-c 6)-alkyl), n[(c 1-c 6)-alkyl]-co-nh-aryl, n[(c 1-c 6)-alkyl]-co-nh-heterocyclic radical, n[(c 1-c 6)-alkyl]-co-n ((c 1-c 6)-alkyl) 2, n[(c 1-c 6)-alkyl]-co-n ((c 1-c 6)-alkyl)-aryl, n[(c 1-c 6)-alkyl]-co-n ((c 1-c 6)-alkyl)-heterocyclic radical, n[(c 1-c 6)-alkyl]-co-n (aryl) 2, n[(c 1-c 6)-alkyl]-co-n (heterocyclic radical) 2, n (aryl)-co-(c 1-c 6)-alkyl, n (heterocyclic radical)-co-(c 1-c 6)-alkyl, n (aryl)-coo-(c 1-c 6)-alkyl, n (heterocyclic radical)-coo-(c 1-c 6)-alkyl, n (aryl)-co-aryl, n (heterocyclic radical)-co-aryl, n (aryl)-coo-aryl, n (heterocyclic radical)-coo-aryl, n (aryl)-co-nh-(c 1-c 6)-alkyl, n (heterocyclic radical)-co-nh-(c 1-c 6)-alkyl, n (aryl)-co-nh-aryl, n (heterocyclic radical)-co-nh-aryl, n (aryl)-co-n ((c 1-c 6)-alkyl) 2, n (heterocyclic radical)-co-n ((c 1-c 6)-alkyl) 2, n (aryl)-co-n[(c 1-c 6)-alkyl]-aryl, n (heterocyclic radical)-co-n[(c 1-c 6)-alkyl]-aryl, n (aryl)-co-n (aryl) 2, n (heterocyclic radical)-co-n (aryl) 2, aryl, o-(ch 2) n-aryl, o-(ch 2) n-heterocyclic radical, wherein n=0-6 and described aryl or heterocyclic radical can be by f, cl, br, i, oh, cf 3, no 2, cn, ocf 3, o-(c 1-c 6)-alkyl, (c 1-c 6)-alkyl, nh 2, nh (c 1-c 6)-alkyl, n ((c 1-c 6)-alkyl) 2, sf 5, so 2-ch 3, cooh, coo-(c 1-c 6)-alkyl, conh 2the single replacement to three replacements; perhaps r1 and r2 form 3 yuan to 8 yuan aryl, cycloalkyl or heterocycles together, and wherein said aryl, cycloalkyl or heterocycle can be by f, cl, br, i, oh, cf 3, no 2, cn, ocf 3, o-(c 1-c 6)-alkyl, (c 1-c 6)-alkyl, nh 2, nh (c 1-c 6)-alkyl, n ((c 1-c 6)-alkyl) 2, sf 5, so 2-ch 3, cooh, coo-(c 1-c 6)-alkyl, conh 2replace and described aryl, cycloalkyl or heterocycle can with other aryl, cycloalkyl or heterocyclic fused.
대사 증후군을 치료하기 위한 치환된 피라논산 유도체의 용도 본 발명은 대사 증후군 치료용 약제를 제조하기 위한, 치환된 피라논산 유도체 및 생리학적으로 허용되는 이의 염의 용도에 관한 것이다. 또한, 본 발명은 대사 증후군 치료용 약제를 제조하기 위한 화학식 I의 화합물 및 생리학적으로 허용되는 이의 염의 용도에 관한 것이다. 화학식 I  위의 화학식 I에서, 라디칼은 명세서에 기재된 바와 같이 정의된다.  대사 증후군 치료용 약제를 제조하기 위한, 화학식 I의 화합물 또는 생리학적으로 허용되는 이의 염의 용도. 화학식 I [이미지] 위의 화학식 I에서, R1은 H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, NH2, NH(C1-C6)-알킬, N((C1-C6)-알킬)2, SF5, SO2-CH3, COOH, COO-(C1-C6)-알킬, CONH2, (C1-C20)-알킬, (C3-C20)-사이클로알킬, (C2-C20)-알케닐, (C2-C20)-알키닐, 아릴 또는 헤테로사이클이고, 여기서 상기 (C1-C20)-알킬 및 (C2-C20)-알케닐 라디칼에서 하나 이상의 개별적인 -CH2- 또는 -CH- 그룹은 -O-에 의해 대체될 수 있고, 여기서 상기 알킬, 사이클로알킬, 알케닐, 알키닐, 아릴- 및 헤테로사이클릴 라디칼은 F, Cl, Br, I, CF3, NO2, N3, CN, =O, COOH, COO(C1-C6)-알킬, CONH2, CONH(C1-C6)-알킬, CON[(C1-C6)-알킬]2, 사이클로알킬, (C1-C10)-알킬, (C2-C6)-알케닐, (C2-C6)-알키닐, O-(C1-C6)-알킬, O-CO-(C1-C6)-알킬, O-CO-(C1-C6)-아릴, O-CO-(C1-C6)-헤테로사이클릴; PO3H2, P(O)(O알킬)2, (C1-C6)-알킬렌-P(O)(O알킬)2, O-P(O)(OH)2, O-P(O)(O알킬)2, SO3H, SO2-NH2, SO2NH(C1-C6)-알킬, SO2N[(C1-C6)-알킬]2, S-(C1-C6)-알킬, S-(CH2)n-아릴, S-(CH2)n-헤테로사이클릴, SO-(C1-C6)-알킬, SO-(CH2)n-아릴, SO-(CH2)n-헤테로사이클릴, SO2-(C1-C6)-알킬, SO2-(CH2)n-아릴, SO2-(CH2)n-헤테로사이클릴, SO2-NH(CH2)n-아릴, SO2-NH(CH2)n-헤테로사이클릴, SO2-N((C1-C6)-알킬)(CH2)n-아릴, SO2-N((C1-C6)-알킬)(CH2)n-헤테로사이클릴, SO2-N((CH2)n-아릴)2, SO2-N((CH2)n-헤테로사이클릴)2(여기서, n은 0 내지 6이고, 상기 아릴 라디칼 또는 헤테로사이클릭 라디칼은 F, Cl, Br, OH, CF3, SF5, NO2, CN, OCF3, O-(C1-C6)-알킬, (C1-C6)-알킬 또는 NH2에 의해 2회 이하 치환될 수 있다); C(NH)(NH2), NH2, NH-(C1-C6)-알킬, N((C1-C6)-알킬)2, NH(C1-C7)-아실, NH-CO-(C1-C6)-알킬, NH-COO-(C1-C6)-알킬, NH-CO-아릴, NH-CO-헤테로사이클릴, NH-COO-아릴, NH-COO-헤테로사이클릴, NH-CO-NH-(C1-C6)-알킬, NH-CO-NH-아릴, NH-CO-NH-헤테로사이클릴, N[(C1-C6)-알킬]-CO-(C1-C6)-알킬, N[(C1-C6)-알킬]-COO-(C1-C6)-알킬, N[(C1-C6)-알킬]-CO-아릴, N[(C1-C6)-알킬]-CO-헤테로사이클릴, N[(C1-C6)-알킬]-COO-아릴, N[(C1-C6)-알킬]-COO-헤테로사이클릴, N[(C1-C6)-알킬]-CO-NH-(C1-C6)-알킬, N[(C1-C6)-알킬]-CO-NH-아릴, N[(C1-C6)-알킬]-CO-NH-헤테로사이클릴, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)2, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)-아릴, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)-헤테로사이클릴, N[(C1-C6)-알킬]-CO-N(아릴)2, N[(C1-C6)-알킬]-CO-N(헤테로사이클릴)2, N(아릴)-CO-(C1-C6)-알킬, N(헤테로사이클릴)-CO-(C1-C6)-알킬, N(아릴)-COO-(C1-C6)-알킬, N(헤테로사이클릴)-COO-(C1-C6)-알킬, N(아릴)-CO-아릴, N(헤테로사이클릴)-CO-아릴, N(아릴)-COO-아릴, N(헤테로사이클릴)-COO-아릴, N(아릴)-CO-NH-(C1-C6)-알킬, N(헤테로사이클릴)-CO-NH-(C1-C6)-알킬, N(아릴)-CO-NH-아릴, N(헤테로사이클릴)-CO-NH-아릴, N(아릴)-CO-N((C1-C6)-알킬)2, N(헤테로사이클릴)-CO-N((C1-C6)-알킬)2, N(아릴)-CO-N[(C1-C6)-알킬]-아릴, N(헤테로사이클릴)-CO-N[(C1-C6)-알킬]-아릴, N(아릴)-CO-N(아릴)2, N(헤테로사이클릴)-CO-N(아릴)2, 아릴, O-(CH2)n-아릴 또는 O-(CH2)n-헤테로사이클릴(여기서, n은 0 내지 6이고, 상기 아릴 또는 헤테로사이클릴 라디칼은 F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-알킬, (C1-C6)-알킬, NH2, NH(C1-C6)-알킬, N((C1-C6)-알킬)2, SF5, SO2-CH3, COOH, COO-(C1-C6)-알킬 또는 CONH2에 의해 1 내지 3회 치환될 수 있다)에 의해 1회 이상 치환될 수 있고, R2는 H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, NH2, NH(C1-C6)-알킬, N((C1-C6)-알킬)2, SF5, SO2-CH3, COOH, COO-(C1-C6)-알킬, CONH2, (C1-C20)-알킬, (C3-C20)-사이클로알킬, (C2-C20)-알케닐, (C2-C20)-알키닐, 아릴 또는 헤테로사이클이고, 여기서 상기 (C1-C20)-알킬 및 (C2-C20)-알케닐 라디칼에서 하나 이상의 개별적인 -CH2- 또는 -CH- 그룹은 -O-에 의해 대체될 수 있고, 여기서 상기 알킬, 사이클로알킬, 알케닐, 알키닐, 아릴 및 헤테로사이클릴 라디칼은 F, Cl, Br, I, CF3, NO2, N3, CN, =O, COOH, COO(C1-C6)-알킬, CONH2, CONH(C1-C6)-알킬, CON[(C1-C6)-알킬]2, 사이클로알킬, (C1-C10)-알킬, (C2-C6)-알케닐, (C2-C6)-알키닐, O-(C1-C6)-알킬, O-CO-(C1-C6)-알킬, O-CO-(C1-C6)-아릴, O-CO-(C1-C6)-헤테로사이클릴; PO3H2, P(O)(O알킬)2, (C1-C6)-알킬렌-P(O)(O알킬)2, O-P(O)(OH)2, O-P(O)(O알킬)2, SO3H, SO2-NH2, SO2NH(C1-C6)-알킬, SO2N[(C1-C6)-알킬]2, S-(C1-C6)-알킬, S-(CH2)n-아릴, S-(CH2)n-헤테로사이클릴, SO-(C1-C6)-알킬, SO-(CH2)n-아릴, SO-(CH2)n-헤테로사이클릴, SO2-(C1-C6)-알킬, SO2-(CH2)n-아릴, SO2-(CH2)n-헤테로사이클릴, SO2-NH(CH2)n-아릴, SO2-NH(CH2)n-헤테로사이클릴, SO2-N((C1-C6)-알킬)(CH2)n-아릴, SO2-N((C1-C6)-알킬)(CH2)n-헤테로사이클릴, SO2-N((CH2)n-아릴)2, SO2-N((CH2)n-헤테로사이클릴)2(여기서, n은 0 내지 6이고, 상기 아릴 라디칼 또는 헤테로사이클릭 라디칼은 F, Cl, Br, OH, CF3, SF5, NO2, CN, OCF3, O-(C1-C6)-알킬, (C1-C6)-알킬 또는 NH2에 의해 2회 이하 치환될 수 있다); C(NH)(NH2), NH2, NH-(C1-C6)-알킬, N((C1-C6)-알킬)2, NH(C1-C7)-아실, NH-CO-(C1-C6)-알킬, NH-COO-(C1-C6)-알킬, NH-CO-아릴, NH-CO-헤테로사이클릴, NH-COO-아릴, NH-COO-헤테로사이클릴, NH-CO-NH-(C1-C6)-알킬, NH-CO-NH-아릴, NH-CO-NH-헤테로사이클릴, N[(C1-C6)-알킬]-CO-(C1-C6)-알킬, N[(C1-C6)-알킬]-COO-(C1-C6)-알킬, N[(C1-C6)-알킬]-CO-아릴, N[(C1-C6)-알킬]-CO-헤테로사이클릴, N[(C1-C6)-알킬]-COO-아릴, N[(C1-C6)-알킬]-COO-헤테로사이클릴, N[(C1-C6)-알킬]-CO-NH-(C1-C6)-알킬, N[(C1-C6)-알킬]-CO-NH-아릴, N[(C1-C6)-알킬]-CO-NH-헤테로사이클릴, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)2, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)-아릴, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)-헤테로사이클릴, N[(C1-C6)-알킬]-CO-N(아릴)2, N[(C1-C6)-알킬]-CO-N(헤테로사이클릴)2, N(아릴)-CO-(C1-C6)-알킬, N(헤테로사이클릴)-CO-(C1-C6)-알킬, N(아릴)-COO-(C1-C6)-알킬, N(헤테로사이클릴)-COO-(C1-C6)-알킬, N(아릴)-CO-아릴, N(헤테로사이클릴)-CO-아릴, N(아릴)-COO-아릴, N(헤테로사이클릴)-COO-아릴, N(아릴)-CO-NH-(C1-C6)-알킬, N(헤테로사이클릴)-CO-NH-(C1-C6)-알킬, N(아릴)-CO-NH-아릴, N(헤테로사이클릴)-CO-NH-아릴, N(아릴)-CO-N((C1-C6)-알킬)2, N(헤테로사이클릴)-CO-N((C1-C6)-알킬)2, N(아릴)-CO-N[(C1-C6)-알킬]-아릴, N(헤테로사이클릴)-CO-N[(C1-C6)-알킬]-아릴, N(아릴)-CO-N(아릴)2, N(헤테로사이클릴)-CO-N(아릴)2, 아릴, O-(CH2)n-아릴 또는 O-(CH2)n-헤테로사이클릴(여기서, n은 0 내지 6이고, 상기 아릴 또는 헤테로사이클릴 라디칼은 F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-알킬, (C1-C6)-알킬, NH2, NH(C1-C6)-알킬, N((C1-C6)-알킬)2, SF5, SO2-CH3, COOH, COO-(C1-C6)-알킬 또는 CONH2에 의해 1 내지 3회 치환될 수 있다)에 의해 1회 이상 치환될 수 있거나, R1과 R2는 함께 3 내지 8원의 아릴, 사이클로알킬 또는 헤테로사이클릴 환을 형성하고, 여기서 상기 아릴, 사이클로알킬 또는 헤테로사이클릴 환은 F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-알킬, (C1-C6)-알킬, NH2, NH(C1-C6)-알킬, N((C1-C6)-알킬)2, SF5, SO2-C...